Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting.. Thank you
Most OTC stocks have their skeletons.. Just need to know how to trade them
Long Term Deposits
Long term deposits are comprised of the following:
On March 3, 2017, the Company entered into a customer purchase agreement whereby the Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 6).
On March 3, 2017, the Company entered into an asset purchase agreement of intellectual property whereby the Company agreed to sell all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell banking business for $50,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 6).
In connection with the March 3, 2017 asset purchase agreement, the CEO and CSO of US Stem Cell, Inc. were also retained as CEO and CSO of American Stem Cell Centers of Excellence, which is owned by General American Capital Partners (GACP), to help with scientific and successful operational deployment of clinics. The Board of Directors of the Company believes that with continued oversight this will not diminish the responsibilities of the CEO and CSO of the Company and contends that the successful deployment of American Stem Cell Centers of Excellence will lead to the financial value and revenue growth of U.S. Stem Cell, Inc. through sales of its products and services at American Stem Cell Center of Excellence clinics.
Concentrations of Credit Risk
The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
As of September 30, 2017, four customers, one of which is a related party (US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), represented 25%, 15%, 16%, and 21% of accounts receivable, respectively, representing an aggregate of 77% of the Company’s accounts receivable. As of December 31, 2016, four customers, one of which is the same related party above, represented 45%, 13%, 13%, and 12% of accounts receivable respectively, representing, an aggregate of 83%, of the Company’s accounts receivable.
NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS
The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during nine months ended September 30, 2017, the Company incurred net losses of $3,828,368 and has a working capital deficit (current liabilities in excess of current assets) of $5,304,333. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
The Company’s primary source of operating funds in 2016 and 2017 has been from revenue generated from sales and cash proceeds from the sale of common stock and the issuance of convertible and other debt. The Company has experienced net losses and negative cash flows from operations since inception, but expects these conditions to improve in 2018 and beyond as it develops its business model. The Company has stockholders’ deficiencies at September 30, 2017 and requires additional financing to fund future operations.
The Company’s existence is dependent upon management’s ability to develop profitable operations, to obtain additional funding sources and realize revenues from the Asset Sale and Lease Agreement described herein. There can be no assurance that the Company’s financing efforts or revenues realized from the Asset Sale and Lease Agreement will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
Looking forward to your updates. Thank you
Looks like NITE will be sitting on the ask until earnings
What will the first hour of trading be like tomorrow ?
Overall still a positive day.
Big Volume in the 1st hour of trading for the 2nd consecutive day. Someone is interested...
3.8 million volume in 60 minutes
2.4 million volume in 30 minutes
We are at .05
USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference
8:30 am ET February 28, 2018 (PR Newswire)
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announces our participation in this year's fourth annual Academy of Regenerative Practices' Conference, which kicks off tomorrow and continues through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida.
https://mma.prnewswire.com/media/614091/US_Stem_Cell_Logo.jpg
The Conference, which hosts some of the world's leading regenerative scientists, health and medical professionals -- including USRM's Chief Science Officer & ARP President Dr. Kristin Comella -- will feature more than 29 speakers including Dr. Joseph Mercola, Dr. Josh Axe & Ben Greenfield.
The annual event also provides doctors and physicians the opportunity to receive hands-on, accredited, continuing education training in performing stem cell procedures. Doctors are able to gain the ability to augment their practice with this cutting-edge, regenerative therapy -- a process that is becoming increasingly in demand amongst the patient population in the United States suffering from neurological, autoimmune, orthopedic and degenerative conditions.
Dr. Comella will be presenting a summary of peer-reviewed publications using a stem cell procedure called Stromal Vascular Fraction (SVF), on Saturday, March 3, at 8:40 a.m. She is well published in the scientific literature through her work at USRM on the application of stem cells and regenerative therapy, including integrating stem cells to improve knee function in cartilage damaged by osteoarthritis; a phase I clinical trial for the use of autologous stem cells in the treatment of end-stage chronic obstructive pulmonary disease; intraglandular injection of stem cells for the treatment of irradiation-induced gland damage post cancer, and the effects of the use of stem cells in patients with chronic ischemic cardiomyopathy.
Dr. Comella, who has more than 20+ years' experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's proprietary Adipocell(TM) product, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells. Once harvested, through a minimally invasive liposuction procedure that is performed while the patient is comfortable but fully awake, the stem cells are then re-injected intravenously or applied directly to a damaged tissue or gland for a more targeted application.
In January, the Company announced Adipocell(TM) reached sales of 10,000+ kits worldwide.
"It's always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate," said Dr. Kristin Comella, USRM's Chief Science Officer and President of the Academy of Regenerative Practices. "This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat. I look forward to another successful conference with my colleagues from around the world."
Autologous stem cell treatments harvested from the patient's own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration. Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell(TM), as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc. 13794 NW 4th Street, Suite 212 Sunrise, Fl 33325 Phone: 954.835.1500 Email: usstemcell@us-stemcell.com
https://c212.net/c/img/favicon.png?sn=FL26150&sd=2018-02-28
View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-chief-science-officer-to-present-at-academy-of-regenerative-practices-conference-300605739.html
SOURCE U.S. Stem Cell, Inc.
Your link ( http://abcnews.go.com/Health/wireStory/us-health-agency-crack-risky-stem-cell-offerings-51200556) on your previous post has no mentioning of this company or your statements of this stock..
1.9 million in volume in the 1st hour
Information stated in this report provided by you is not as you stated in your post
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=ACADEMYREGENERATIVEPRACTICES%20P160000167710&aggregateId=domp-p16000016771-2a9cf9b4-b0af-4b79-8ff3-a902508e4f45&searchTerm=academy%20of%20regenerative&listNameOrder=ACADEMYREGENERATIVEPRACTICES%20N140000101310
USRM Responds to Lawsuit Filed for Discontinued Eye Treatments
7:00 am ET December 20, 2017 (PR Newswire)
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week in Broward County by a plaintiff claiming she had an adverse event for a voluntary stem cell procedure at a doctor's office utilizing autologous (the patient's own) stem cells to attempt to reverse the effects of macular degeneration-- a disease that currently has no cure.
The adverse event the plaintiff claims she experienced as a result of the treatment, which was administered by a doctor in February of 2015, is a detached retina in one eye, which the patient alleges has led to loss of sight in that eye. Counsel for the patient also claims that his client's vision has worsened in the other eye. As the lawsuit was just filed, these allegations have not been corroborated. USRM's AdipoCell(TM) kit was used to harvest autologous cells from the patient's fat tissue.
The use of autologous stem cells for macular degeneration was discontinued by US Stem Cell Clinic, a separate company, as of June of 2015, after adverse events were reported.
"We have addressed any concerns about using AdipoCell(TM) for macular degeneration by discontinuing its use since more than two years ago," said Dr. Kristin Comella, USRM's Chief Science Officer. "Because we have seen strong safety profiles using AdipoCell(TM) to harvest autologous stem cells to treat a wide variety of other conditions -- including orthopedic, autoimmune, degenerative and neurological diseases -- we are instead focusing our development at this time on these more broad arenas."
"Publicly traded companies are always a target for law suits," said Mike Tomas, President & CEO of U.S. Stem Cell, Inc. "Every lawsuit is different, we are confident that our attorneys -- who are very familiar with the issues surrounding this case -- will investigate and defend this claim so that this case is resolved as soon as legally practical."
U.S. Stem Cell and its affiliated entities did not administer the treatment to the patient. The procedure was performed by an outside practitioner, who is among the hundreds of trained doctors worldwide who utilize U.S. Stem Cell, Inc. technology. U.S. Stem Cell does not currently treat eye patients, and for nearly 20 years, clinics have safely conducted thousands of stem cell procedures utilizing our protocol. We remain committed to the development of effective cell technologies to treat patients with a variety of diseases and injuries.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell(TM), as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy
8:00 am ET February 6, 2018 (PR Newswire)
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics -- a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
https://mma.prnewswire.com/media/614091/US_Stem_Cell_Logo.jpg
As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, "The Healing Miracle: The Truth About Stem Cells," will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.
"Our phones are ringing off the hook," said Dr. Comella. "Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain. Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments," said Dr. Comella.
Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.
"We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further," said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. "We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product," said Tomas. "We believe this is an indicator of continued growth to come."
Dr. Comella, who has more than 20+ years' experience and is one of the world's leading stem cell scientists, can be seen in The Healing Miracle docuseries here. To view Dr. Comella's interview online, click the link and fill out the information, which will provide complimentary access.
To access Dr. Comella's live webinar this Friday, Feb. 9, at Noon EST, click here to register or join. Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company's website and its Facebook page (https://www.facebook.com/USStemCellInc/).
USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Old News
CEO Blog: February 2018
Posted by U.S. Stem Cell, Inc
Dear Shareholders and Friends,
Thank you all so much for taking the time to learn more about our recent progress. In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.
A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.
We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily. Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.
We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases. We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.
The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice. Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.
USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential. We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients. We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.
Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases. As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace. We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time. We are confident that timing is now.
USRM technologies are now offered in six continents with interest from various countries throughout the world growing. We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles. These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them. We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.
The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain. Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population. Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells. Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy. Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.
Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform. “Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants. Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.
In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield. The webinar, which is entitled “Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance. Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine. He was successful at increasing both size and rate of performance. To listen to that webinar in its entirety click here.
Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology. We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.
Warmest regards,
Mike Tomas,
President and CEO
Correction, ABC news is no longer a credible source for news.
"Enhancing Sexual Performance with Stem Cell Therapy," will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST. To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689
USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker
8:30 am ET February 14, 2018 (PR Newswire) Print
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar open to the public with Ben Greenfield -- a leading biohacker and fitness expert and CEO of health company Kion-- who recently had penile stem cell injections to enhance sexual performance.
https://mma.prnewswire.com/media/614091/US_Stem_Cell_Logo.jpg
"Enhancing Sexual Performance with Stem Cell Therapy," will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST. To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689
Greenfield, a self-professed 'biohacker' who recently received stromal vascular fraction treatments (SVF) for erectile enhancement as part of his ongoing exploration of optimal physical performance, including penile enhancement, says as a result of the treatment he has experienced penile enlargement and more frequent erections.
"My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment," said Greenfield. "The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now."
"Because so many patients are seeking holistic alternatives to sustain sexual performance, and because it's Valentine's Day, we thought it would be the perfect opportunity to discuss the use of autologous stem cells in this arena," said Dr. Kristin Comella, USRM's Chief Science Officer. "Ben's experience and his willingness to be open about sharing his journey will give a lot of people the opportunity to ask questions in an anonymous setting, so that they can learn more about whether the benefits of SVF is right for them."
SVF involves using USRM's proprietary AdipocellTM kit to help isolate a patient's own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine's January 2017 issue.
Autologous stem cell treatments harvested from the patient's own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) -- a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.
"Enhancing Sexual Performance with Stem Cells," is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy. The first webinar, "Facts About Stem Cell Therapy," which was broadcast live last Friday, can be accessed as a playback here: http://www.brainshark.com/Stemlogix/vu?pi=zHEz136Dfmz5OLvz0
Dr. Comella, who has more than 20+ years' experience and is one of the world's leading stem cell scientists, is also featured in the recent Jeff Hays docuseries "The Healing Miracle: The Truth About Stem Cells." (Click here to view Dr. Comella's interview from THM in its entirety.) It was her participation in the docuseries that inspired her to launch the webinar series.
Greenfield, who was voted in 2013 and 2014 as one of the world's top 100 most influential people in health and fitness by Greatist, coaches top CEO's, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond - all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor's degree and master's degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.
USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Fake News
To access Dr. Comella's live webinar this Friday, Feb. 9, at Noon EST, click here to register or join. Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company's website and its Facebook page (https://www.facebook.com/USStemCellInc/).
We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further,
106% increase in revenues during the 3rd Q
"Our phones are ringing off the hook," said Dr. Comella. "Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain.
NEWS.. USRM Seeing Explosive Increase in Demand for Stem Cell Therapy
8:00 am ET February 6, 2018 (PR Newswire) Print
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics -- a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
https://mma.prnewswire.com/media/614091/US_Stem_Cell_Logo.jpg
As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, "The Healing Miracle: The Truth About Stem Cells," will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.
"Our phones are ringing off the hook," said Dr. Comella. "Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain. Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments," said Dr. Comella.
Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.
"We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further," said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. "We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product," said Tomas. "We believe this is an indicator of continued growth to come."
Dr. Comella, who has more than 20+ years' experience and is one of the world's leading stem cell scientists, can be seen in The Healing Miracle docuseries here. To view Dr. Comella's interview online, click the link and fill out the information, which will provide complimentary access.
To access Dr. Comella's live webinar this Friday, Feb. 9, at Noon EST, click here to register or join. Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company's website and its Facebook page (https://www.facebook.com/USStemCellInc/).
USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.13794 NW 4th Street, Suite 212Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com
https://c212.net/c/img/favicon.png?sn=FL07184&sd=2018-02-06
View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-seeing-explosive-increase-in-demand-for-stem-cell-therapy-300594102.html
SOURCE U.S. Stem Cell, Inc.
https://rt.prnewswire.com/rt.gif?NewsItemId=FL07184&Transmission_Id=201802060800PR_NEWS_USPR_____FL07184&DateId=20180206
Did anyone participate in the Healing Miracle Q & A last night?
NEWS...SUNRISE, Fla., Jan. 24, 2018
SUNRISE, Fla., Jan. 24, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, has been featured in the docuseries, "The Healing Miracle: The Truth About Stem Cells" -- a film that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy.
(PRNewsfoto/U.S. Stem Cell, Inc.)
Dr. Comella, who has more than 20+ years' experience and is one of the world's leading stem cell scientists, has been involved in more than 10,000 stem cell procedures at USRM since 2001. USRM has pioneered stem cell therapy for damaged tissue from a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's Adipocell™ , a stem cell kit which enables physicians to separate stem cells from a patient's own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
In the documentary, Dr. Comella (who has worked with all kinds of stem cells including, bone, muscle and fat), recounts an emotional experience with a patient who presented with a two-year-old head trauma and was wheelchair bound. Following her stem cell protocol with Dr. Comella and USRM, she had a life-changing experience.
Americans in general have been relatively uninformed about the availability of the field of stem cell therapy and regenerative medicine as an option for treating chronic pain conditions, damaged tissue and life-threatening illness. 'The Healing Miracle,' which is produced by Jeff Hays Films, is on a mission to change that trend by shining a light on a field of medicine that has been somewhat sidelined by U.S. regulatory agencies. Last November, the FDA issued a long-awaited statement indicating it is moving toward integrating stem cell therapy into its code of practice, but concluded by giving itself three years to determine whether it will heavily regulate stem cells in humans as drugs, or continue to allow individuals to have free access to their own healing reserves of stem cells.
"The purpose of this interview is to educate people about cellular medicine -- a concept that has been overshadowed by a pharmaceutical industry that has used disassociation and fear to distract patients from their own healing capabilities," said Dr. Comella. "This documentary is a great way for the public to learn more about regenerative options available to them -- an alternative to chronic, long-term drug use to managing symptoms, which we all know is often accompanied by debilitating side effects. There has never been a better time to bring this forward than now, to explore healing regenerative therapies... facing a national emergency around pain management and opioid misuse is a clear wake up call that it's time for better methods."
Dr. Comella is featured in episode 5 of the docuseries, which is available in its entirety online. To watch just Dr. Comella's interview, click the Brainshark link here and fill out the information which will provide complimentary access.
"We are so proud of Dr. Comella. The world's growing interest in her work and about stem cell therapy and regenerative medicine is an indication our time has come," said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. "Stem cell therapy is rapidly becoming a part of mainstream medicine, and USRM is poised to take the lead in offering this treatment worldwide."
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™ , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Phone: 954.835.1500
Email: usstemcell@us-stemcell.com
Cision View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-chief-science-officer-featured-in-powerful-stem-cell-docuseries-300587473.html
SOURCE U.S. Stem Cell, Inc.
Copyright © 2018 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
USRM Reaches Key Sales Milestone of Proprietary Adipocell(TM) Product
8:30 am ET January 15, 2018 (PR Newswire)
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell(TM) product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM's proprietary stem cell products and services.
https://mma.prnewswire.com/media/614091/US_Stem_Cell_Logo.jpg
Adipocell(TM), which has been developed, marketed and distributed by USRM, enables physicians to separate potent stem cells from a patient's own (autologous) fat cells, which are harvested and reinserted in two-hours total, in a minimally invasive procedure. Stem cells are an important component of the body's ability to regenerate itself, and are rapidly becoming a mainstream trend in the field of regenerative medicine.
USRM is the premiere company in the United States that markets and manufactures an autologous adipose/stem cell separation kit. Autologous cells are not rejected by the body's immune system and, as a result, may be more compatible and effective in reversing damage and augmenting health.
In addition to trailblazing the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, USRM also has developed a training program for physicians who want to learn how to offer stem cell therapy to their patients.
In-person training involves a two-day, interactive, hands-on training course at USRM's Sunrise, Florida-based clinic, and includes integration of autologous cellular treatments, the extraction of lipoaspirate and bone marrow aspirate, as well as demonstrations on how to isolate adipose and bone-marrow-derived stem cells. Physician trainees will participate in several cases and perform clinical procedures under the supervision of an experienced instructor on a total of 3-5 patients. Cost for physician participation is $7,500.
Online training offers physicians clinical training in a web-based format. Consistent with in-person training, online training focuses on autologous cellular treatments like adult stem cells and platelet-rich plasma. Physicians will learn the basics of stem therapy and have the option to obtain preceptor on-site training. Cost for physician participation is $2,500.
On-site training is available for physicians who have completed in-person or online training, and involves a USRM stem-cell specialist providing the physician one-on-one, on-site training at the physician's own clinic.
"This is a key milestone for us as a Company, and for regenerative medicine in general, as it demonstrates the increasing demand in the marketplace for our Adipocell(TM) product," said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. "We are dedicated and proud to lead the way on a global scale for the emergence of this novel therapeutic."
"Our commitment to making regenerative, stem cell therapy available to any physician worldwide who is interested in providing stem cell therapy to their patients is reflected in our day-to-day practices as an organization," said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. "The need for readily available stem cell procedures that physicians can offer their patients as an alternative to addictive pain medications, which has caused an opioid crisis in America, proves the time for regenerative medicine as a part of regular physician practice and pain management is long overdue."
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell(TM), as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.13794 NW 4th Street, Suite 212Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com
https://c212.net/c/img/favicon.png?sn=FL87446&sd=2018-01-15
View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-reaches-key-sales-milestone-of-proprietary-adipocell-product-300582298.html
SOURCE U.S. Stem Cell, Inc.
USRM Stem Cell Treatment Shows Promise in Enhancing Erectile Function
8:30 am ET January 8, 2018 (PR Newswire) Print
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement. Details of the procedure and the results are featured in the January issue of Men's Health, on newsstands now.
Greenfield, whose experience following the treatments includes more frequent erections and penile enlargement, received his first of two treatments at the USRM clinic in Sunrise, Florida.
Stromal vascular fraction treatments, or autologous stem cell treatments harvested from the patient's own fat, could provide healthier alternatives to use of pharmaceuticals for erectile enhancement and dysfunction (ED) -- a market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. Greenfield, who is a self-professed 'biohacker,' sought treatment as part of his ongoing exploration of 'biohacking' and penile enhancement.
"My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment," said Greenfield. "The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now."
Stromal vascular fraction involves using USRM's proprietary AdipoCellTM kit to help isolate a patient's own stem cells from the fat cells. Studies of stromal vascular fraction's used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine's January 2017 issue.
"Autologous stem cell therapy is rapidly entering the arena of mainstream regenerative medicine, as is exemplified by its acceptance, use and promotion by cutting edge biohackers and fitness experts like Mr. Greenfield," said Dr. Kristin Comella, USRM's Chief Science Officer. "As regenerative stem cell therapy continues to expand into specialized markets, we look forward to broadening our application for these voluntary procedures."
Greenfield, who was voted in 2013 and 2014 as one of the world's top 100 most influential people in health and fitness by Greatist, coaches top CEO's, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond - all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor's degree and master's degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.
"Last year was about restructuring debt and streamlining our financials in order to position ourselves in 2018 for these kinds of opportunities," said Mike Tomas, USRM's Chief Executive Officer. "We look forward to continuing to explore the application of stromal vascular fraction treatments for a wide variety of voluntary procedures which is being driven by market demand for more holistic, autologous therapies."
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell(TM), as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.13794 NW 4th Street, Suite 212Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com
https://c212.net/c/img/favicon.png?sn=FL82435&sd=2018-01-08
View original content:http://www.prnewswire.com/news-releases/usrm-stem-cell-treatment-shows-promise-in-enhancing-erectile-function-300578817.html
SOURCE U.S. Stem Cell, Inc.
USRM Responds to Lawsuit Filed for Discontinued Eye Treatments
7:00 am ET December 20, 2017 (PR Newswire) Print
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week in Broward County by a plaintiff claiming she had an adverse event for a voluntary stem cell procedure at a doctor's office utilizing autologous (the patient's own) stem cells to attempt to reverse the effects of macular degeneration-- a disease that currently has no cure.
The adverse event the plaintiff claims she experienced as a result of the treatment, which was administered by a doctor in February of 2015, is a detached retina in one eye, which the patient alleges has led to loss of sight in that eye. Counsel for the patient also claims that his client's vision has worsened in the other eye. As the lawsuit was just filed, these allegations have not been corroborated. USRM's AdipoCell(TM) kit was used to harvest autologous cells from the patient's fat tissue.
The use of autologous stem cells for macular degeneration was discontinued by US Stem Cell Clinic, a separate company, as of June of 2015, after adverse events were reported.
"We have addressed any concerns about using AdipoCell(TM) for macular degeneration by discontinuing its use since more than two years ago," said Dr. Kristin Comella, USRM's Chief Science Officer. "Because we have seen strong safety profiles using AdipoCell(TM) to harvest autologous stem cells to treat a wide variety of other conditions -- including orthopedic, autoimmune, degenerative and neurological diseases -- we are instead focusing our development at this time on these more broad arenas."
"Publicly traded companies are always a target for law suits," said Mike Tomas, President & CEO of U.S. Stem Cell, Inc. "Every lawsuit is different, we are confident that our attorneys -- who are very familiar with the issues surrounding this case -- will investigate and defend this claim so that this case is resolved as soon as legally practical."
U.S. Stem Cell and its affiliated entities did not administer the treatment to the patient. The procedure was performed by an outside practitioner, who is among the hundreds of trained doctors worldwide who utilize U.S. Stem Cell, Inc. technology. U.S. Stem Cell does not currently treat eye patients, and for nearly 20 years, clinics have safely conducted thousands of stem cell procedures utilizing our protocol. We remain committed to the development of effective cell technologies to treat patients with a variety of diseases and injuries.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell(TM), as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.13794 NW 4th Street, Suite 212Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com
https://c212.net/c/img/favicon.png?sn=FL74435&sd=2017-12-20
View original content:http://www.prnewswire.com/news-releases/usrm-responds-to-lawsuit-filed-for-discontinued-eye-treatments-300573702.html
SOURCE U.S. Stem Cell, Inc.
Degenerative Disc Patients Significantly Improve with USRM's Adipocell(TM)
8:30 am ET November 28, 2017 (BusinessWire) Print
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Chief Science Officer Dr. Kristin Comella will present clinical data demonstrating safety and efficacy of its proprietary Adipocell(TM) therapy in treating degenerative disc disease -- a condition that affects more than 65 million Americans annually(1) -- at the Annual Meeting for International Federation for Adipose Therapeutics and Science (IFATS).
Dr. Comella, who is a global leader in the development of revolutionary holistic stem cell therapies, will discuss her paper "Effects of the Intradiscal Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in Patients With Degenerative Disc Disease," on Thursday, November 30, 5:30 p.m., at the Lowes Hotel Miami Beach. Dr. Comella's presentation will also be live streamed at www.facebook.com/comella.stem.cell/.
The study, which included 15 patients with degenerative disc disease, featured the use of USRM's proprietary Adipocell(TM)therapy following a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue. Adipocell(TM) kits and enzymewere used to separate and isolate a patient's own stromal vascular fraction (SVF) which was then delivered into the disc of patients.
Patients were then monitored for 6 months for adverse events, range of motion, visual analog scale (VAS), present pain intensity (PPI), Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), Dallas Pain Questionnaire and Short Form (SF)-12 scores. Safety events were also monitored, for a 12-month period.
The procedure demonstrated a strong safety profile with no severe adverse events (SAEs) or complications linked to the therapy they received, and no incidences of infection. Patients who participated in this study experienced statistically significant improvements in several parameters including flexion, pain ratings, VAS, PPI, and short form questionnaires. In addition, both ODI and BDI data was trending positive and a majority of patients reported improvements in their Dallas Pain Questionnaire scores. More importantly, patients overall were pleased with treatment results.
"We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless," said Dr. Comella, who co-authored the study along with two colleagues. "We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one."
IFATS is a non-profit scientific society currently dedicated to scientific areas of interest related to facilitating the development of treatments for excess body fat, the generation of new fat tissue for reconstruction after cancer or birth-related defects and the use of adipose tissue as a source of mesenchymal stem cells that have the potential to regenerate and repair different body tissues.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician/veterinary training and certification and stem cell products and protocols. USRM also provides stem cell banking for patients and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
(1)American Association of Neurological Surgeons & the Congress of Neurological Surgeons.
About U.S. Stem Cell, Inc.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20171128005819r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005819/en/
SOURCE: U.S. Stem Cell, Inc.">
We need to acquire additional financing or our business will fail.
We must obtain additional capital or our business will fail. In order to continue development of our eBalance Technology and to successfully complete clinical trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on. We currently have no arrangements for additional financing. We may also have to borrow large sums of money that require substantial capital and interest payments.
Risks related to our stock
We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.
Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue. However there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.
There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.
Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.
Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.
Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.
Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.
Recent Corporate Developments
The following corporate developments occurred during the quarter ended November 30, 2016, and up to the date of the filing of this report:
Letter Agreement with Jean Arnett and Brad Hargreaves
On September 26, 2016, we entered into a letter agreement (the “Letter Agreement”) with Jean Arnett and Brad Hargreaves to, among other things, cancel the unvested portion of the options granted to Ms. Arnett and Mr. Hargreaves pursuant to those separate Option Agreements between us and Ms. Arnett, and Mr. Hargreaves, each dated for reference November 25, 2014 (the “Cancelled Options”). The Cancelled Options had previously entitled Ms. Arnett and Mr. Hargreaves to collectively acquire up to 17,500,000 common shares of the Company (8,750,000 shares, each) at an initial price of $0.05 per share.
In addition, we renegotiated our consulting arrangements with Ms. Arnett and Mr. Hargreaves. Based on the Letter Agreement, we agreed to pay each of Ms. Arnett and Mr. Hargreaves CAD$5,000 per month, beginning effective August 1, 2016, for a duration of six (6) months.
Appointment of Director
On September 26, 2016, the board of directors of the Company unanimously resolved to fix the number of directors at three, and appointed Yanika Silina, our current Chief Financial Officer, as a director to fill the vacancy created by the increase in the number of directors. We did not enter into any new compensation arrangements with Ms. Silina in connection with her appointment as a director of the Company.
Private Placement Offering
On October 12, 2016, we closed a non-brokered private placement offering (the “Offering”) at a price of $0.15 per unit, by issuing 2,383,333 units for cash proceeds of $357,500 and 6,711,272 units to the holders of our notes payable for debt settlement of $1,006,691. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.
Loan Agreements
During the quarter ended November 30, 2016, we did not enter into any loan agreements, subsequent to November 30, 2016, we entered into loan agreements for a total of CAD$55,000, of which CAD$15,000 were loaned to us by Mr. Richard Jeffs, our major shareholder. The loans bear interest at 6% per annum, compounded monthly, are unsecured and payable on demand.
On September 30, 2016, Mr. Jeffs notified us that he had assigned all rights to his claims against the Company in the amount of $250,000 to two unaffiliated parties (the “Assignees”). The full amount of debt assigned to the Assignees was converted into the units of the Company’s common stock as part of the Offering.
$.001 per share, outstanding as of January 17, 2017 was 40,244,605.